Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Immunotherapy Tops CRISPR Agenda

Andrew D. Smith
Published: Thursday, Feb 01, 2018
Marcela V. Maus, MD, PhD

Marcela V. Maus, MD, PhD
The gene-editing tool known as CRISPR may eventually enable oncology investigators to create methods for killing tumors directly—or even for preventing people from ever developing cancer—but thus far, the focus is on enhancing forms of immunotherapy already in clinical practice.


Figure. Components of the CRISPR-CAS9 System for Gene Editing

Components of the Crispr-CAS9
This interesting discovery became a practical tool in 2012, when a team led by Jennifer A. Doudna, PhD, and Emmanuelle Charpentier, PhD, reported that investigators could make Cas9 chop up the DNA of any molecule they wanted, in a precise location, by deliberately inserting RNA into a CRISPR-carrying enzyme.1 The potential to dramatically change medical research bercame evident just 1 year later, when teams led by Feng Zhang, PhD, and George M. Church, PhD, discovered how to use CRISPR to exchange any DNA researchers wanted for any that they needed to chop out.2,3
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication